Lewes, DE -- (SBWIRE) -- 10/20/2016 -- Report forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus.

The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

According to the report, improvement in diagnostic technologies is a key driver aiding to the growth of this market. There has been an increase in research activities involved in the development of various diagnostic tools for cystic fibrosis. For instance, scientists at Stanford University have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. This test utilizes the next-generation DNA sequencing which can identify the entire CFTR gene rather than just looking at selected mutations. This is considered to be less expensive and less time-consuming technology, which will contribute to this market's growth in the coming years.

Further, the report states that difficulty in developing drugs due to rarity of disease is a major challenge the market is facing. The rare diseases often pose a challenge to drug manufacturers as the identification of targets for the development of the disease, and the conduction of clinical trials in the patient population becomes difficult. It has been estimated that the prevalence of the rare disease is usually five in 10,000 in the EU, and there are only around 200,000 individuals in the US. This small population creates a hurdle for the proper evaluation of the disease during the clinical trials. Also, in diseases with less severe symptoms, patients do not generally seek medical attention, and this will lead to underestimation of the condition and will hinder the development of effective treatments.

Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global cystic fibrosis therapeutics market: Vertex Pharmaceuticals, F. Hoffmann-La Roche, AbbVie, Gilead Sciences, and Novartis.

Other Prominent Vendors in the market are: Advanced Inhalation Therapies (AIT), Alaxia SAS, Alcresta Therapeutics, AlgiPharma, Allergan, Anthera, AstraZeneca, Bayer, Celtaxsys, Chiesi Farmaceutici, Corbus Pharmaceuticals, Cyclacel Pharmaceuticals, Digestive Care, Galapagos, Grifols, Insmed Incorporated, Kamada, Nivalis Therapeutics, Novoteris, Parion Sciences, Pharmaxis, ProQR Therapeutics, Protalix Biotherapeutics, Proteostasis Therapeutics, PTC Therapeutics, Pulmatrix, Savara, SolAeroMed, and Vectura.

Market driver
- Special regulatory designations for drugs
- For a full, detailed list, view our report

Market challenge
- Discontinuation of drugs from development
- For a full, detailed list, view our report

Market trend
- Co-pay and assistance programs by vendors
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 80 pages and 62 Exhibits "Global Cystic Fibrosis Therapeutics Market 2016 - 2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Pipeline analysis, Market segmentation by drug class, Market segmentation by molecule type, Geographical segmentation, Key leading countries, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.marketresearchreports.com/technavio/global-cystic-fibrosis-therapeutics-market-2016-2020

Related Reports;

Global Lumbar Spine Fusion Market 2016-2020 - Visit at - http://www.marketresearchreports.com/technavio/global-lumbar-spine-fusion-market-2016-2020

Global Dental Services Market 2016-2020 - Visit at - http://www.marketresearchreports.com/technavio/global-dental-services-market-2016-2020

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions